Elusys Therapeutics Commends U.S. Congress for Introduction of H.R. 2707, Bolstering Anthrax Preparedness

Elusys Invited to Present LAV-BASTA-48 Anthrax Vaccine at the Annual Defense Threat Reduction Agency (DTRA) Chemical and Biological Science & Technology Annual Conference

Elusys Executes Initial Procurement Contract to Deliver ANTHIM® to the Canadian Government

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax

Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax

Elusys Therapeutics receives Health Canada approval for Anthim® for the treatment for Inhalation Anthrax